Abstract
The continued development of computational and synthetic methods has enabled the enumeration or preparation of a nearly endless universe of chemical structures. Nevertheless, the ability of this chemical universe to deliver small molecules that can both modulate biological targets and have drug-like physicochemical properties continues to be a topic of interest to the pharmaceutical industry and academic researchers alike. The chemical space described by public, commercial, in-house and virtual compound collections has been interrogated by multiple approaches including biochemical, cellular and virtual screening, diversity analysis, and in-silico profiling. However, current drugs and known chemical probes derived from these efforts are contained within a remarkably small volume of the predicted chemical space. Access to more diverse classes of chemical scaffolds that maintain the properties relevant for drug discovery is certainly needed to meet the increasing demands for pharmaceutical innovation. The Lilly Open Innovation Drug Discovery platform (OIDD) was designed to tackle barriers to innovation through the identification of novel molecules active in relevant disease biology models. In this article we will discuss several computational approaches towards describing novel, biologically active, drug-like chemical space and illustrate how the OIDD program may facilitate access to previously untapped molecules that may aid in the search for innovative pharmaceuticals.
Keywords: Open innovation, chemical space, drug discovery.
Current Topics in Medicinal Chemistry
Title:Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space
Volume: 14 Issue: 3
Author(s): Maria Alvim-Gaston, Timothy Grese, Abdelaziz Mahoui, Alan D. Palkowitz, Marta Pineiro-Nunez and Ian Watson
Affiliation:
Keywords: Open innovation, chemical space, drug discovery.
Abstract: The continued development of computational and synthetic methods has enabled the enumeration or preparation of a nearly endless universe of chemical structures. Nevertheless, the ability of this chemical universe to deliver small molecules that can both modulate biological targets and have drug-like physicochemical properties continues to be a topic of interest to the pharmaceutical industry and academic researchers alike. The chemical space described by public, commercial, in-house and virtual compound collections has been interrogated by multiple approaches including biochemical, cellular and virtual screening, diversity analysis, and in-silico profiling. However, current drugs and known chemical probes derived from these efforts are contained within a remarkably small volume of the predicted chemical space. Access to more diverse classes of chemical scaffolds that maintain the properties relevant for drug discovery is certainly needed to meet the increasing demands for pharmaceutical innovation. The Lilly Open Innovation Drug Discovery platform (OIDD) was designed to tackle barriers to innovation through the identification of novel molecules active in relevant disease biology models. In this article we will discuss several computational approaches towards describing novel, biologically active, drug-like chemical space and illustrate how the OIDD program may facilitate access to previously untapped molecules that may aid in the search for innovative pharmaceuticals.
Export Options
About this article
Cite this article as:
Alvim-Gaston Maria, Grese Timothy, Mahoui Abdelaziz, Palkowitz D. Alan, Pineiro-Nunez Marta and Watson Ian, Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space, Current Topics in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/1568026613666131127125858
DOI https://dx.doi.org/10.2174/1568026613666131127125858 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation
Protein & Peptide Letters Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters Breast Cancer in the Personal Genomics Era
Current Genomics Meet Our Editorial Board Member
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Flame Retardants in Indoor Dust - A Review on the Levels of Polybrominated Diphenyl Ethers and Hexabromocyclododecanes
Current Organic Chemistry Metal Ion Transport Across Metal-organic Pyrogallol[4]arene-based Nanocapsules
Current Organic Chemistry Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology Assembled Core-Shell Nanostructures of Gold Nanoparticles with Biocompatible Polymers Toward Biology
Current Topics in Medicinal Chemistry Dual Time F-18 FDG PET/CT Imaging in the Diagnosis of Renal Cell Cancer
Current Medical Imaging Increasing Hippocampal Neurogenesis: A Novel Mechanism for Antidepressant Drugs
Current Pharmaceutical Design The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy
Current Diabetes Reviews Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Dyslipidemia, Hypertension and Diabetes Metaflammation: A Unique Mechanism for 3 Risk Factors
Current Hypertension Reviews Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging
Current Neuropharmacology Mobile Phone Based Health Care Technology
Recent Patents on Biomedical Engineering (Discontinued) Mechanisms of Protein Aggregation
Current Pharmaceutical Biotechnology High Prevalence of AH in HIV Patients on ART, in Bahia, Brazil
Current HIV Research Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging
Current Molecular Pharmacology Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued)